{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:55:42Z","timestamp":1786485342714,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019725","name":"DEBRA Austria","doi-asserted-by":"publisher","award":["PEBLES 3"],"award-info":[{"award-number":["PEBLES 3"]}],"id":[{"id":"10.13039\/501100019725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Debra UK","award":["Mellerio 1"],"award-info":[{"award-number":["Mellerio 1"]}]},{"name":"Debra Research","award":["PEBLES 4"],"award-info":[{"award-number":["PEBLES 4"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic disease, including different forms of epidermolysis bullosa (EB), may significantly impair health-related quality of life (HRQoL). To date, HRQoL in specific subtypes of recessive dystrophic EB (RDEB) has not been studied in depth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To measure HRQoL in a large cohort of individuals with different RDEB subtypes, to explore differences in physical functioning and emotional\/psychosocial health scores, and to identify potential correlation with disease severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Prospective EB Longitudinal Evaluation Study (PEBLES) is a register study of children and adults with RDEB. Reviews are repeated every 6 months (under 10 years) or annually (10 years and above) with HRQoL assessed using the Quality of Life in Epidermolysis Bullosa (QOLEB), an EB-specific questionnaire, for adult participants and the Pediatric Quality of Life Inventory (PedsQL) generic core scales, version 4.0, for child participants and their parents. Disease severity was measured with the Birmingham EB Severity score (BEBS) and the Instrument for Scoring Clinical Outcomes for EB (iscorEB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      HRQoL was reported in 335 reviews over a maximum of seven years by 61 participants: severe RDEB (RDEB-S)\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926, intermediate (RDEB-I)\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921, inversa (RDEB-Inv)\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099, pruriginosa (RDEB-Pru)\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094 and pretibial RDEB\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091. QOLEB demonstrated a severe impact on HRQoL for all RDEB adults (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947), particularly for RDEB-Pru and RDEB-S participants. Total and functioning QOLEB scores correlated with disease severity scores (iscorEB, BEBS) for all RDEB, with a statistically higher impact in RDEB-S compared to RDEB-I and RDEB-Inv. In children (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914), those with greater disease severity measured by iscorEB also reported worse HRQoL (PedsQL). In adults and children, physical functioning\/health QoL was more severely impacted than emotions\/psychosocial health, and HRQoL generally improved with age.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results highlight a significant impact on HRQoL in adults and children with all types of RDEB which generally correlates with disease severity. Relatively less impact on emotional functioning\/psychosocial health rather than physical functioning\/health scores suggests psychological adaptation from living with RDEB, a lifelong condition which typically presents at or shortly after birth. Further, a relative improvement in HRQoL with age, despite disease progression and increasing severity over time, supports ongoing adaptation throughout life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04330-5","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:59:13Z","timestamp":1778025553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Health-related quality of life in recessive dystrophic epidermolysis bullosa: findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES)"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6695-354X","authenticated-orcid":false,"given":"Eunice","family":"Jeffs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth I.","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesedi","family":"Ledwaba-Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bisquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemima E.","family":"Mellerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"4","key":"4330_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614\u201327.","journal-title":"Br J Dermatol"},{"issue":"1","key":"4330_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.det.2009.10.019","volume":"28","author":"JW Frew","year":"2010","unstructured":"Frew JW, Murrell DF. Quality of life measurements in epidermolysis bullosa: tools for clinical research and patient care. Dermatol Clin. 2010;28(1):185\u201390. https:\/\/doi.org\/10.1016\/j.det.2009.10.019.","journal-title":"Dermatol Clin"},{"issue":"1","key":"4330_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5021\/ad.2016.28.1.6","volume":"28","author":"IK Jeon","year":"2016","unstructured":"Jeon IK, On HR, Kim SC. Quality of life and economic burden in recessive dystrophic epidermolysis bullosa. Ann Dermatol. 2016;28(1):6\u201314.","journal-title":"Ann Dermatol"},{"issue":"3","key":"4330_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jaad.2009.03.052","volume":"61","author":"JD Fine","year":"2009","unstructured":"Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol. 2009;61(3):367\u201384.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4330_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jaad.2009.03.053","volume":"61","author":"JD Fine","year":"2009","unstructured":"Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol. 2009;61(3):387\u2013402.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4330_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/BF00370713","volume":"287","author":"J Uitto","year":"1994","unstructured":"Uitto J, Christiano AM. Molecular basis for the dystrophic forms of epidermolysis bullosa: mutations in the type VII collagen gene. Arch Dermatol Res. 1994;287(1):16\u201322.","journal-title":"Arch Dermatol Res"},{"key":"4330_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.matbio.2018.04.001","volume":"71\u201372","author":"C Has","year":"2018","unstructured":"Has C, Nystr\u00f6m A, Saeidian AH, Bruckner-Tuderman L, Uitto J. Epidermolysis bullosa: Molecular pathology of connective tissue components in the cutaneous basement membrane zone. Matrix Biol. 2018;71\u201372:313\u201329.","journal-title":"Matrix Biol"},{"issue":"2","key":"4330_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","volume":"60","author":"JD Fine","year":"2009","unstructured":"Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986\u20132006. J Am Acad Dermatol. 2009;60(2):203\u201311.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"4330_CR9","doi-asserted-by":"publisher","first-page":"adv00523","DOI":"10.2340\/00015555-3875","volume":"101","author":"SJ Robertson","year":"2021","unstructured":"Robertson SJ, Orrin E, Lakhan MK, O\u2019Sullivan G, Felton J, Robson A, et al. Cutaneous squamous cell carcinoma in epidermolysis bullosa: a 28-year retrospective study. Acta Derm Venereol. 2021;101(8):adv00523.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"4330_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/jmg.2010.082230","volume":"48","author":"PC van den Akker","year":"2011","unstructured":"van den Akker PC, Mellerio JE, Martinez AE, Liu L, Meijer R, Dopping-Hepenstal PJ, et al. The inversa type of recessive dystrophic epidermolysis bullosa is caused by specific arginine and glycine substitutions in type VII collagen. J Med Genet. 2011;48(3):160\u20137.","journal-title":"J Med Genet"},{"issue":"5","key":"4330_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1365-2133.1994.tb13109.x","volume":"130","author":"JA McGrath","year":"1994","unstructured":"McGrath JA, Schofield OMV, Eady RAJ. Epidermolysis bullosa pruriginosa: dystrophic epidermolysis bullosa with distinctive clinicopathological features. Br J Dermatol. 1994;130(5):617\u201325.","journal-title":"Br J Dermatol"},{"issue":"4","key":"4330_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/1049732308315110","volume":"18","author":"C van Scheppingen","year":"2008","unstructured":"van Scheppingen C, Lettinga AT, Duipmans JC, Maathuis KG, Jonkman MF. The main problems of parents of a child with epidermolysis bullosa. Qual Health Res. 2008;18(4):545\u20136.","journal-title":"Qual Health Res"},{"issue":"2","key":"4330_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2340\/00015555-0376","volume":"88","author":"C van Scheppingen","year":"2008","unstructured":"van Scheppingen C, Lettinga AT, Duipmans JC, Maathuis CG, Jonkman MF. Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews. Acta Derm Venereol. 2008;88(2):143\u201350.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"4330_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","volume":"15","author":"AL Bruckner","year":"2020","unstructured":"Bruckner AL, Losow M, Wisk J, Patel N, Reha A, Lagast H, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020;15(1):1.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4330_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13023-023-02817-z","volume":"18","author":"JE Mellerio","year":"2023","unstructured":"Mellerio JE, Pillay EI, Ledwaba-Chapman L, Bisquera A, Robertson SJ, Papanikolaou M, et al. Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study. Orphanet J Rare Dis. 2023;18(1):235.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4330_CR16","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1002\/ski2.314","volume":"4","author":"E Jeffs","year":"2024","unstructured":"Jeffs E, Pillay E, Ledwaba-Chapman L, Bisquera A, Robertson S, McGrath J, et al. Costs of UK community care for individuals with recessive dystrophic epidermolysis bullosa: Findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study. Skin Health Dis. 2024;4(1):e314.","journal-title":"Skin Health Dis"},{"issue":"1","key":"4330_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s13023-024-03349-w","volume":"19","author":"E Jeffs","year":"2024","unstructured":"Jeffs E, Pillay EI, Ledwaba-Chapman L, Bisquera A, Robertson SJ, McGrath JA, et al. Pain in recessive dystrophic epidermolysis bullosa (RDEB): findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES). Orphanet J Rare Dis. 2024;19(1):375.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"4330_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1046\/j.1365-2230.2002.01121.x","volume":"27","author":"HM Horn","year":"2002","unstructured":"Horn HM, Tidman MJ. Quality of life in epidermolysis bullosa. Clin Exp Dermatol. 2002;27(8):707\u201310.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"4330_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1177\/1049732311400431","volume":"21","author":"E Dures","year":"2011","unstructured":"Dures E, Morris M, Gleeson K, Rumsey N. The psychological impact of epidermolysis bullosa. Qual Health Res. 2011;21(6):771\u201382.","journal-title":"Qual Health Res"},{"issue":"Suppl 1","key":"4330_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10198-016-0783-4","volume":"17","author":"A Angelis","year":"2016","unstructured":"Angelis A, Kanavos P, L\u00f3pez-Bastida J, Linertov\u00e1 R, Oliva-Moreno J, Serrano-Aguilar P, et al. Social\/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. Eur J Health Econ. 2016;17(Suppl 1):31\u201342.","journal-title":"Eur J Health Econ"},{"issue":"5PartB","key":"4330_CR21","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ijwd.2021.08.007","volume":"7","author":"F Chogani","year":"2021","unstructured":"Chogani F, Mahdi Parvizi M, Murrell DF, Handdjani F. Assessing the quality of life in the families of patients with epidermolysis bullosa: The mothers as main caregivers. Int J Womens Dermatol. 2021;7(5PartB):721\u20136.","journal-title":"Int J Womens Dermatol"},{"issue":"5","key":"4330_CR22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/j.1365-2133.2004.06339.x","volume":"152","author":"JD Fine","year":"2005","unstructured":"Fine JD, Johnson LB, Weiner M, Suchindran C. Impact of inherited epidermolysis bullosa on parental interpersonal relationships, marital status and family size. Br J Dermatol. 2005;152(5):1009\u201314.","journal-title":"Br J Dermatol"},{"issue":"4","key":"4330_CR23","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1365-2133.2009.09306.x","volume":"161","author":"S Tabolli","year":"2009","unstructured":"Tabolli S, Sampogna F, Di Pietro C, Paradisi A, Uras C, Zotti P, et al. Quality of life in patients with epidermolysis bullosa. Br J Dermatol. 2009;161(4):869\u201377.","journal-title":"Br J Dermatol"},{"issue":"5","key":"4330_CR24","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jaad.2020.03.028","volume":"85","author":"VA Eng","year":"2021","unstructured":"Eng VA, Solis DC, Gorell ES, Choi S, Nazaroff J, Li S, et al. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey. J Am Acad Dermatol. 2021;85(5):1161\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"4330_CR25","doi-asserted-by":"crossref","unstructured":"Togo CCG, Zid\u00f3rio APC, Goncalves VSS, Hubbard L, de Carvalho KMB, Dutra ES. Quality of life in people with epidermolysis bullosa: a systematic review. Qual Life Res. 2020;29:1731\u201345.","DOI":"10.1007\/s11136-020-02495-5"},{"issue":"2","key":"4330_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/pde.12262","volume":"31","author":"EA Eismann","year":"2014","unstructured":"Eismann EA, Lucky AW, Cornwall R. Hand function and quality of life in children with epidermolysis bullosa. Pediatr Dermatol. 2014;31(2):176\u201382.","journal-title":"Pediatr Dermatol"},{"key":"4330_CR27","first-page":"3","volume-title":"World Health Organization. Handbook of basic documents","author":"Constitution of the World Health Organization. In","year":"1952","unstructured":"Constitution of the World Health Organization. In. World Health Organization. Handbook of basic documents. 5th ed. Geneva: Palais des Nations; 1952. pp. 3\u201320.","edition":"5"},{"issue":"8","key":"4330_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jama.1994.03520080061045","volume":"272","author":"TM Gill","year":"1994","unstructured":"Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272(8):619\u201326.","journal-title":"JAMA"},{"key":"4330_CR29","doi-asserted-by":"publisher","unstructured":"Carpi M, Gatti F, De Vincenzo C. The EuroQol-5D questionnaires: a brief outline. Occup Med (Lond). 2025;23:kqaf130. https:\/\/doi.org\/10.1093\/occmed\/kqaf130.","DOI":"10.1093\/occmed\/kqaf130"},{"issue":"1","key":"4330_CR30","first-page":"352","volume":"19","author":"I Aranda-Reneo","year":"2024","unstructured":"Aranda-Reneo I, Oliva-Moreno J, Pe\u00f1a-Longobardo LM, Villar-Hern\u00e1ndez \u00c1R, L\u00f3pez-Bastida J. Economic burden and health-related quality of life in patients with epidermolysis bullosa in Spain. J Rare Dis. 2024;19(1):352.","journal-title":"J Rare Dis"},{"issue":"3","key":"4330_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"4330_CR32","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"4330_CR33","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1365-2133.2009.09347.x","volume":"161","author":"JW Frew","year":"2009","unstructured":"Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: An EB-specific quality of life instrument. Br J Dermatol. 2009;161(6):1323\u201330.","journal-title":"Br J Dermatol"},{"issue":"4","key":"4330_CR34","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jaad.2013.04.053","volume":"69","author":"JW Frew","year":"2013","unstructured":"Frew JW, Cepeda Valdes R, Fortuna G, Murrell DF, Salas Alanis J. Measuring quality of life in epidermolysis bullosa in Mexico: cross-cultural validation of the Hispanic version of the Quality of Life in Epidermolysis Bullosa questionnaire. J Am Acad Dermatol. 2013;69(4):652\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"4330_CR35","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1111\/ijd.12819","volume":"55","author":"T Cestari","year":"2016","unstructured":"Cestari T, Prati C, Menegon DB, Prado Oliveira ZN, Machado MC, Dumet J, et al. Translation, cross-cultural adaptation and validation of the Quality of Life Evaluation in Epidermolysis Bullosa instrument in Brazilian Portuguese. Int J Dermatol. 2016;55(2):e94\u20139.","journal-title":"Int J Dermatol"},{"issue":"2","key":"4330_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.25259\/IJDVL_31_20","volume":"88","author":"A Bishnoi","year":"2022","unstructured":"Bishnoi A, Manjunath S, Kishore K, De D, Handa S, Murrell DF, Mahajan R. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022;88(2):177\u201383.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"12","key":"4330_CR37","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.3390\/ijerph19127059","volume":"19","author":"AR Villar Hern\u00e1ndez","year":"2022","unstructured":"Villar Hern\u00e1ndez AR, Molero Alonso F, Aguado Mar\u00edn \u00c1J, de la Posada M. Transcultural validation of a Spanish version of the Quality of Life in Epidermolysis Bullosa questionnaire. Int J Environ Res Public Health. 2022;19(12):7059.","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"4330_CR38","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1177\/13591053231221369","volume":"30","author":"G Salamon","year":"2025","unstructured":"Salamon G, Strobl S, Field-Werners U, Welponer T, Murrell DF, Diem A. Translation, cultural adaptation and validation of the German Quality of Life in Epidermolysis Bullosa (QOLEB) questionnaire. J Health Psychol. 2025;30(7):1476\u201390.","journal-title":"J Health Psychol"},{"issue":"4","key":"4330_CR39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ijwd.2020.05.012","volume":"6","author":"A Yazdanshenas","year":"2020","unstructured":"Yazdanshenas A, Naderi E, Moravvej H, Heidari K, Faghankhani M, Vahidnezhad H, Mozafari N. The quality of life in epidermolysis bullosa (EB-QoL) questionnaire: Translation, cultural adaptation, and validation into the Farsi language. Int J Womens Dermatol. 2020;6(4):301\u20135.","journal-title":"Int J Womens Dermatol"},{"issue":"1","key":"4330_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13052-024-01657-2","volume":"50","author":"M El Hachem","year":"2024","unstructured":"El Hachem M, Diociaiuti A, Zambruno G, Samela T, Ferretti F, Carnevale C, et al. Quality of Life in Epidermolysis Bullosa and Epidermolysis Bullosa Burden of Disease. Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires. Ital J Pediatr. 2024;50(1):76.","journal-title":"Ital J Pediatr"},{"issue":"4","key":"4330_CR41","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2340\/00015555-1758","volume":"94","author":"WY Yuen","year":"2014","unstructured":"Yuen WY, Frew JW, Veerman K, van den Heuvel ER, Murrell DF, Jonkman MF. Health-related quality of life in epidermolysis bullosa: Validation of the Dutch QOLEB questionnaire and assessment in the Dutch population. Acta Derm Venereol. 2014;94(4):442\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"4330_CR42","first-page":"119","volume":"12","author":"J Brun","year":"2017","unstructured":"Brun J, Chiaverini C, Devos C, Leclerc-Mercier S, Mazereeuw J, Bourrat E, et al. Pain and quality of life evaluation in patients with localized epidermolysis bullosa simplex. J Rare Dis. 2017;12(1):119.","journal-title":"J Rare Dis"},{"issue":"5","key":"4330_CR43","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/pde.14802","volume":"38","author":"S Fulchand","year":"2021","unstructured":"Fulchand S, Harris N, Li S, Barriga M, Gorell E, De Souza M, et al. Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey. Pediatr Dermatol. 2021;38(5):1198\u2013201.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"4330_CR44","first-page":"270","volume":"17","author":"JY So","year":"2022","unstructured":"So JY, Fulchand S, Wong CY, Li S, Nazaroff J, Gorell ES, et al. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex. J Rare Dis. 2022;17(1):270.","journal-title":"J Rare Dis"},{"issue":"1","key":"4330_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/bjd\/ljae019","volume":"191","author":"G Salamon","year":"2024","unstructured":"Salamon G, Strobl S, Field-Werners U, Diem A, Schwieger-Briel A, Pope E. Psychometric properties of the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa patient score (iscorEB-p): a patient-reported outcome measure. Br J Dermatol. 2024;191(1):75\u201381.","journal-title":"Br J Dermatol"},{"issue":"5","key":"4330_CR46","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1111\/jdv.15371","volume":"33","author":"S D\u0103nescu","year":"2019","unstructured":"D\u0103nescu S, S\u0103l\u0103v\u0103stru C, Sendrea A, Tiplica S, Baican A, Ungureanu L, et al. Correlation between disease severity and quality of life in patients with epidermolysis bullosa. Eur Acad Dermatol Venereol. 2019;33(5):e217\u20139.","journal-title":"Eur Acad Dermatol Venereol"},{"issue":"5","key":"4330_CR47","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/bjd.16350","volume":"178","author":"AL Bruckner","year":"2018","unstructured":"Bruckner AL, Fairclough DL, Feinstein JA, Lara-Corrales I, Lucky AW, Tolar J, Pope E. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB). Br J Dermatol. 2018;178(5):1128\u201334.","journal-title":"Br J Dermatol"},{"issue":"8","key":"4330_CR48","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800\u201312.","journal-title":"Med Care"},{"issue":"5","key":"4330_CR49","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1365-2133.2009.09041.x","volume":"160","author":"C Moss","year":"2009","unstructured":"Moss C, Wong A, Davies P. The Birmingham Epidermolysis Bullosa Severity score: development and validation. Br J Dermatol. 2009;160(5):1057\u201365.","journal-title":"Br J Dermatol"},{"key":"4330_CR50","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.","edition":"2"},{"issue":"1","key":"4330_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s44192-025-00209-2","volume":"5","author":"G Martins Freitas","year":"2025","unstructured":"Martins Freitas G, Claure LH, de Andrade FA, Purim KSM. The impact of epidermolysis bullosa on quality of life and mental health. Discov Ment Health. 2025;5(1):83.","journal-title":"Discov Ment Health"},{"issue":"1","key":"4330_CR52","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13023-022-02461-z","volume":"17","author":"AS Paller","year":"2022","unstructured":"Paller AS, Pope E, Rudin D, Malyala A, Ramsdell DD, Johnson R, et al. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17(1):314.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"4330_CR53","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/ijd.17668","volume":"64","author":"PV Chernyshov","year":"2025","unstructured":"Chernyshov PV, Finlay AY, Tomas-Aragones L, Poot F, Murrell DF, Pustisek N, Svensson A, Marron SE, Sampogna F, Bewley A, Salavastru C, Koumaki D, Suru A, Yordanova IA, Zemskov S, Tsymbaliuk R, Ostapko O, Augustin M, Abeni D, Szepietowski JC, Jemec GB. Quality-of-Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient-Oriented Outcomes and External Experts. Int J Dermatol. 2025;64(9):1546\u201357.","journal-title":"Int J Dermatol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04330-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04330-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04330-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:59:51Z","timestamp":1781650791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04330-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4330"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04330-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PEBLES was ethically approved by the UK Research Ethics Committee and Health Research Authority (IRAS 142032) and all participants completed an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors give consent for publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}